Paul A. Bunn, Jr. | MD
James Dudley Chair in Cancer Research
Distinguished Professor of Medicine and founding former Director of the University of Colorado Cancer Center
Dr. Bunn is a former Executive Director of IASLC, the former President of ASCO, IASLC, and AACI, and former Chairman of the FDA Oncology Drug Advisory Committee. Dr. Bunn received his medical degree from Weill Medical College of Cornell University, New York. Dr. Bunn completed his internship and residency at the University Of California. His post-graduate training includes a fellowship at the National Capital Consortium. Dr. Bunn’s research interests are on novel therapies for lung cancer. He has published more than 300 articles in peer-reviewed journals, 122 reviews and 90 book chapters on lung cancer. Dr. Bunn’s studies have set standards for the treatment of lung cancer, have identified issues of natural history of the disease and have identified biomarkers of prognosis and therapy selection. Dr. Bunn is the principal investigator on numerous national and local therapeutic trials and is also the principal investigator for the SPORE grant in lung cancer that is designed to conduct translational research.
S. Gail Eckhardt | MD
Associate Dean of Cancer Programs
Director, LIVESTRONG Cancer Institutes, Professor of Medicine – Dell Medical School, University of Texas at Austin
Dr. Eckhardt has served on the Board of Directors of the American Society of Clinical Oncology (ASCO) as well as numerous committees and study sections, including the GI Steering Committee of the Southwest Oncology Group, the ASCO Molecular Oncology Task Force and the EORTC Early Clinical Trials Review Panel. She has served as Chair of the FDA’s Oncology Drug Advisory Committee and currently serves on the Colorectal Cancer Task Force and the Investigational Drug Steering Committee of the NCI. Dr. Eckhardt is the Principal Investigator on an NCI grant involving early clinical trials research and has conducted numerous phase I and II clinical trials. She has published over 170 manuscripts. Dr. Eckhardt received her medical degree from the University of Texas Medical Branch in Galveston, Texas, and her internship and residency at the University of Virginia Medical Center in Charlottesville. Her postgraduate training included a research fellowship in the Division of Experimental and Molecular Medicine at Scripps Clinic and Research Foundation, and a medical oncology and research fellowship at the University of California, San Diego School of Medicine. Prior to her move to The Dell Medical School, Dr. Eckhardt served as Professor of Medicine and Head of Medical Oncology at the University of Colorado Cancer Center. Dr. Eckhardt founded the Phase I Program at the University of Colorado Cancer Center in 1999 which enrolls over 200 cancer patients per year on trials of novel agents.
Antonio Jimeno | MD, PhD
Professor of Medicine/Oncology and Otolaryngology, University of Colorado Anschutz Medical Campus, Daniel and Janet Mordecai Endowed Chair for Cancer Stem Cell Research
Director Head and Neck Cancer Clinical Research Program, Director, Cancer stem cell-directed Clinical Trials Program, University of Colorado Cancer Center and Charles C. Gates Center of Stem Cell Biology
Dr. Jimeno trained in Internal Medicine and Medical Oncology in Madrid, Spain, where he also obtained his Ph.D. in 2003. Then he continued his training with a Drug Development Clinical Fellowship at Johns Hopkins University (2003-2005), where he later was an Instructor of Oncology (2006-2008). Dr. Jimeno joined the UCSOM Faculty in April 2008 as an Assistant Professor of Medicine. In 2010 he became an Associate Professor and the Director of the Head and Neck Cancer Medical Oncology Program, as well as the Director of the Cancer Stem Cell directed Clinical Trials Program (a joint collaboration between the Gates Center for Stem Cell Biology and the University of Colorado Cancer Center). In 2014 he became a Professor of Medicine. He is also the Daniel and Janet Mordecai Endowed Chair for Cancer Stem Cell Research. Dr. Jimeno has an interest in integrating preclinical research, drug development, and clinical research in head and neck squamous cell cancers. His aim is to bridge the lab and the clinic by 1) developing direct patient xenograft models of head and neck and other cancers to generate better cancer models and as a platform to study cancer stem cells, 2) conducting preclinical tests of targeted agents against de-regulated pathways and cancer stem cells, and 3) devising ways to integrate that knowledge into clinical trials to individualize anti-cancer therapy. His concomitant work in the laboratory and the clinic has materialized in the form of novel inventions (drugs and biomarkers) that are currently the subject of prospective clinical testing. He has been recognized for his research efforts with an ASCO Young Investigator Award in 2005, and two ASCO Merit Awards in 2004 and 2006. He is the author of over 90 original research manuscripts, over 50 reviews, over 12 patents, and holds peer-review research from multiple organizations including the National Institutes of Health, and the Department of Defense. He is the Principal Investigator of over 25 clinical trials, both Phase 1 trials in patients with solid tumors, and Phase 1 and 2 studies for patients with head and neck squamous cell cancers. He is married to another physician-scientist, Ana Fernandez-Bustamante M.D., Ph.D. from the Department of Anesthesiology at UCSOM, and they have three kids.
Garry Nolan | PhD
Professor of Microbiology and Immunology, Stanford University School of Medicine
Director, Stanford Single Cell Proteomics Center
Co-founder: Rigel, Nodality, IonPath, Apprise, Akoya, BINA
Dr. Nolan is the author of over 200 peer-reviewed papers and holds numerous issued patents. He is the recipient of several prestigious awards including an honor as one of the top 25 inventors at Stanford University. He was the first recipient of the Teal Innovator Award from the Department of Defense, named for the “Invention of the Year” in 2012 by Nature Magazine, was a Trustee of the Leukemia Society of America (1995-98), Burroughs Welcome Fund New Investigator Awardee (1996-2000), HHMI Junior Faculty Scholar Awardee, Leukemia and Lymphoma Society Stohlman Scholar (2000), among others. He is the co-founder of 6 companies, including publicly traded RIGEL (NASDAQ:RIGL), Chair of the SAB of DVS (sold to Fluidigm for $207million) and BINA (sold to Roche for $120million). Dr. Nolan received his PhD in the Department of Genetics at Stanford with flow cytometry pioneer Leonard Herzenberg and was a postdoctoral fellow in the laboratory of Dr. David Baltimore at MIT and Rockefeller University.
David Raben | MD FASTRO
VP, Product Development Oncology, Global Head LASR Franchise at Genentech, Professor of Radiation Oncology
Dr. Raben is nationally recognized for his work in targeted therapies and radiation, primarily in GI, head and neck cancer and lung cancer. He served on the head and neck cancer steering committee of the National Cancer Institute (NCI) sponsored radiation cooperative group (RTOG). In addition, he was a member of the genitourinary section of the Southwest Oncology Group (SWOG). Dr. Raben was the first radiation oncologist in the Rocky Mountain region to implement accelerated intensity modulated radiation to the prostate and pelvis. Dr. Raben received his medical degree from Wake Forest University, North Carolina. Dr. Raben completed his internship at the University of Hawaii Medical School, Honolulu, and his residency in radiation oncology at the Johns Hopkins Hospital. Dr. Raben currently leads the Lung, Agnostic, Skin, Head and Neck and rare Cancers (LASR) franchise in late stage development at Genentech.